Simple view
Full metadata view
Authors
Statistics
Clinical application of 1,5-anhydroglucitol measurements in patients with hepatocyte nuclear factor-1α maturity-onset diabetes of the young
OBJECTIVE - 1,5-anhydroglucitol (1,5-AG) is a short-term marker of metabolic control in diabetes. Its renal loss is stimulated in hyperglycemic conditions by glycosuria, which results in a lowered plasma concentration. As a low renal threshold for glucose has been described in hepatocyte nuclear factor-1α (HNF-1α) maturity-onset diabetes of the young (MODY), the 1,5-AG level may be altered in these patients. The purpose of this study was to assess the 1,5-AG levels in patients with HNF-1α MODY and in type 2 diabetic subjects with a similar degree of metabolic control. In addition, we aimed to evaluate this particle as a biomarker for HNF-1α MODY. RESEARCH DESIGN AND METHODS - We included 33 diabetic patients from the Polish Nationwide Registry of MODY. In addition, we examined 43 type 2 diabetic patients and 47 nondiabetic control subjects. The 1,5-AG concentration was measured with an enzymatic assay (GlycoMark). Receiver operating characteristic (ROC) curve analysis was used to evaluate 1,5-AG as a screening marker for HNF-1α MODY. RESULTS - The mean 1,5-AG plasma concentration in diabetic HNF-1α mutation carriers was 5.9 μg/ml, and it was lower than that in type 2 diabetic patients (11.0 μg/ml, P = 0.003) and in nondiabetic control subjects (23.9 μg/ml, P < 0.00005). The ROC curve analysis revealed 85.7% sensitivity and 80.0% specificity of 1,5-AG in screening for HNF-1α MODY at the criterion of <6.5 μg/ml in patients with an A1C level between 6.5 and 9.0%. CONCLUSIONS - 1,5-AG may be a useful biomarker for differential diagnosis of patients with HNF-1α MODY with a specific range of A1C, although this requires further investigation. However, the clinical use of this particle in diabetic HNF-1α mutation carriers for metabolic control has substantial limitations.
cris.lastimport.wos | 2024-04-10T00:54:36Z | |
dc.abstract.en | OBJECTIVE - 1,5-anhydroglucitol (1,5-AG) is a short-term marker of metabolic control in diabetes. Its renal loss is stimulated in hyperglycemic conditions by glycosuria, which results in a lowered plasma concentration. As a low renal threshold for glucose has been described in hepatocyte nuclear factor-1α (HNF-1α) maturity-onset diabetes of the young (MODY), the 1,5-AG level may be altered in these patients. The purpose of this study was to assess the 1,5-AG levels in patients with HNF-1α MODY and in type 2 diabetic subjects with a similar degree of metabolic control. In addition, we aimed to evaluate this particle as a biomarker for HNF-1α MODY. RESEARCH DESIGN AND METHODS - We included 33 diabetic patients from the Polish Nationwide Registry of MODY. In addition, we examined 43 type 2 diabetic patients and 47 nondiabetic control subjects. The 1,5-AG concentration was measured with an enzymatic assay (GlycoMark). Receiver operating characteristic (ROC) curve analysis was used to evaluate 1,5-AG as a screening marker for HNF-1α MODY. RESULTS - The mean 1,5-AG plasma concentration in diabetic HNF-1α mutation carriers was 5.9 μg/ml, and it was lower than that in type 2 diabetic patients (11.0 μg/ml, P = 0.003) and in nondiabetic control subjects (23.9 μg/ml, P < 0.00005). The ROC curve analysis revealed 85.7% sensitivity and 80.0% specificity of 1,5-AG in screening for HNF-1α MODY at the criterion of <6.5 μg/ml in patients with an A1C level between 6.5 and 9.0%. CONCLUSIONS - 1,5-AG may be a useful biomarker for differential diagnosis of patients with HNF-1α MODY with a specific range of A1C, although this requires further investigation. However, the clinical use of this particle in diabetic HNF-1α mutation carriers for metabolic control has substantial limitations. | pl |
dc.affiliation | Wydział Lekarski : Klinika Chorób Metabolicznych | pl |
dc.affiliation | Wydział Lekarski : Katedra Chorób Metabolicznych | pl |
dc.affiliation | Wydział Lekarski : Katedra Chorób Wewnętrznych i Medycyny Wsi | pl |
dc.contributor.author | Skupień, Jan - 152464 | pl |
dc.contributor.author | Gorczyńska-Kosiorz, Sylwia | pl |
dc.contributor.author | Klupa, Tomasz - 130157 | pl |
dc.contributor.author | Wanic, Krzysztof | pl |
dc.contributor.author | Button, Eric A. | pl |
dc.contributor.author | Sieradzki, Jacek | pl |
dc.contributor.author | Małecki, Maciej - 130840 | pl |
dc.date.accessioned | 2020-08-27T12:59:12Z | |
dc.date.available | 2020-08-27T12:59:12Z | |
dc.date.issued | 2008 | pl |
dc.date.openaccess | 0 | |
dc.description.accesstime | w momencie opublikowania | |
dc.description.number | 8 | pl |
dc.description.physical | 1496-1501 | pl |
dc.description.version | ostateczna wersja wydawcy | |
dc.description.volume | 31 | pl |
dc.identifier.doi | 10.2337/dc07-2334 | pl |
dc.identifier.eissn | 1935-5548 | pl |
dc.identifier.issn | 0149-5992 | pl |
dc.identifier.project | ROD UJ / OP | pl |
dc.identifier.uri | https://ruj.uj.edu.pl/xmlui/handle/item/244744 | |
dc.language | eng | pl |
dc.language.container | eng | pl |
dc.rights | Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Bez utworów zależnych 3.0 | * |
dc.rights.licence | CC-BY-NC-ND | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode | * |
dc.share.type | inne | |
dc.subtype | Article | pl |
dc.title | Clinical application of 1,5-anhydroglucitol measurements in patients with hepatocyte nuclear factor-1α maturity-onset diabetes of the young | pl |
dc.title.journal | Diabetes Care | pl |
dc.type | JournalArticle | pl |
dspace.entity.type | Publication |
* The migration of download and view statistics prior to the date of April 8, 2024 is in progress.
Views
11
Views per month
Views per city
Downloads
Open Access